171 results on '"Supiot, Stephane"'
Search Results
2. Urinary Organs at Risk for Prostate Cancer External Beam Radiation Therapy: Contouring Guidelines on Behalf of the Francophone Group of Urological Radiation Therapy
3. The carbon footprint of external beam radiotherapy and its impact in health technology assessment
4. Kidney transplantation after pelvic radiotherapy: Increased morbidity?
5. Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review
6. How to contour the different heart subregions for future deep-learning modeling of the heart: A practical pictorial proposal for radiation oncologists
7. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies
8. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer
9. Consensus Delineation Guidelines for Pelvic Lymph Node Radiation Therapy of Prostate Cancer: On Behalf of the Francophone Group of Urological Radiation Therapy (GFRU)
10. Salvage radiotherapy after initial cryotherapy for localized prostate cancer: A systematic review of the literature
11. Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)
12. Respective Roles of Surgery, Chemotherapy, and Radiation Therapy for Recurrent Pediatric and Adolescent Ependymoma: A National Multicentric Study
13. Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study
14. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study
15. Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol
16. Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group
17. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
18. ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.
19. Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy
20. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer:A Systematic Review and Meta-analysis of Prospective Studies
21. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups
22. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population
23. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
24. Prise en charge des rechutes oligométastatiques des cancers de prostate : actualités et perspectives
25. LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY
26. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
27. Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy
28. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)
29. Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children’s cancer
30. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
31. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies
32. Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial
33. Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013
34. Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma
35. Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?
36. 2601: Guidelines-based automatic segmentation improvements
37. 1225: Radiotherapy Quality Assurance over the course of time, a systematic literature review
38. 849: Relapse Risk stratification in pediatric ependymoma patients using clinical data and radiomics
39. Dosimetric feasibility of dose-painting radiotherapy for targeting hypoxia in prostate cancer on a novel ring gantry radiotherapy system.
40. Radiothérapie pratique des métastases osseuses : indications et techniques
41. Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma
42. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.
43. Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07)
44. High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study
45. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
46. First evidence of in vivo effect of FLASH radiotherapy with helium ions in zebrafish embryos
47. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer
48. Supplementary Fig. S1 from Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
49. Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
50. Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.